Unlocking the Blood-Brain Barrier: Can Low-Intensity Focused Ultrasound Enable Effective Delivery of Anti-Amyloid and Anti-Tau Antibodies in Alzheimer's Disease?
Alzheimer's disease (AD) remains a major unmet medical challenge despite decades of progress in medicines that target tau and amyloid-β (Aβ) pathology. The clinical benefit of monoclonal antibodies (mAbs) against Aβ is limited, with current data showing only slight slowing of cognitive decline despite encouraging bioma...